



Effient[®] (prasugrel) – First-time Generic

- On August 15, 2017, Mylan and Prasco launched their respective generic versions of Eli Lilly's [Effient \(prasugrel\)](#) tablets.
 - Mylan's product is an [AB-rated](#) generic to brand Effient.
 - Prasco's product is an authorized generic to brand Effient.
 - Mylan has 60 days of market exclusivity. Additional generics are expected to enter the market on October 14, 2017.
- Effient is indicated to reduce the rate of thrombotic cardiovascular (CV) events (including stent thrombosis) in patients with acute coronary syndrome who are to be managed with percutaneous coronary intervention (PCI) as follows: patients with unstable angina or non-ST-elevation myocardial infarction (MI), and patients with ST-elevation MI when managed with primary or delayed PCI.
 - Effient has been shown to reduce the rate of a combined endpoint of cardiovascular death, nonfatal MI, or nonfatal stroke compared to clopidogrel. The difference between treatments was driven predominantly by MI, with no difference on strokes and little difference on CV death.



OptumRx[®] specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum[®] company — a leading provider of integrated health services. Learn more at [optum.com](#).

All Optum[®] trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews[®] is published by the OptumRx Clinical Services Department.

©2017 Optum, Inc. All rights reserved.